Search Within

Even Holth Rustad

  1. "Caleb Ho"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (5)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Department of Pathology and Laboratory Medicine (13)
  4. Hematologic Malignancies Research (13)
  5. Hematologic Malignancies, Division of (13)
  6. Myeloma (13)

More Groups

People
  1. Caleb Ho (13)
  2. Carl Landgren (12)
  3. Maria Arcila (12)
  4. Malin Hultcrantz (11)
  5. Mikhail Roshal (11)
  6. Venkata Yellapantula (9)

More People

Years
  1. 2021 (4)
  2. 2020 (3)
  3. 2019 (5)
  4. 2018 (1)
Publications
  1. Blood (6)
  2. American Journal of Hematology (1)
  3. Blood Cancer Journal (1)
  4. Blood Reviews (1)
  5. JAMA Oncology (1)
  6. Journal of Molecular Diagnostics (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. Elsevier Science, Inc. (2)
  3. American Medical Association (1)
  4. Churchill Livingstone (1)
  5. John Wiley & Sons, Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity
    Review

    Diamond, B. T.; Rustad, E.; Maclachlan, K.; Thoren, K.; Ho, C.; Roshal, M.; Ulaner, G. A.; Landgren, C. O.
    Blood Reviews (2021)

    Fulltext@MSK | Save
  • Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: Feasibility, challenges, and direct comparison with high-sensitivity flow cytometry
    Journal Article

    Ho, C.; Syed, M.; Roshal, M.; Petrova-Drus, K.; Moung, C.; Yao, J.; Quesada, A. E.; Benhamida, J.; Vanderbilt, C.; Liu, Y.; more...
    Journal of Molecular Diagnostics (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Baseline VDJ clonotype detection using a targeted sequencing NGS assay: Allowing for subsequent MRD assessment
    Research Letter

    Hultcrantz, M.; Rustad, E. H.; Yellapantula, V.; Arcila, M.; Ho, C.; Syed, M. H.; Papaemmanuil, E.; Zhang, Y.; Maura, F.; Landgren, O.
    Blood Cancer Journal (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Plasma cell myeloma residual disease quantitation using a next-generation sequencing-based IGH clonal rearrangement assay with the aid of a "spike-in" clonal sequence
    Meeting Abstract

    Ho, C.; Syed, M.; Yu, W.; Petrova-Drus, K.; Yao, J. J.; Moung, C.; Chang, J.; Benhamida, J.; Vanderbilt, C.; Roshal, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save